Market Recap — October 24, 2026
Recap of insider activity, SEC filings, and market-moving news for October 24, 2026.
Last generated Nov 3, 2026, 10:09 PM ET
Top Importance Today
Filings and news with the highest AI-ranked importance score.
Imfinzi Combo Cuts Bladder Cancer Death Risk 42% in Phase III VOLGA Trial
Imdelltra-Imfinzi Combo Cuts Lung Cancer Death Risk 58% in Phase 3
Zolucatetide Hits 72% Response Rate in Desmoid Tumors; FDA Aligns on Phase 3
Melanoma Combo Cuts Recurrence Risk ~42% as Analysts Split on Moderna
Robot Consulting Appeals Nasdaq Delisting, Trading Halt Persists
Audi Pledges $4.2B Georgia Plant Producing 200K SUVs a Year
Climb Bio's pMN Drug Shows B-Cell Depletion, Remission at 12 Weeks in Early Phase 2
BeOne's GPC3 Bispecific Hits 36% ORR in Liver Cancer; Registrational Trials Planned by Year-End
Tesla Slashes Capex to $20B as Operating Income Falls 56%
J&J Sets Mid-2027 DePuy Spin as $20–22B Orthopedics Valuation Circulates; UK Clears Icotyde
Darolutamide Cuts Metastasis or Death Risk 58% in High-Risk Prostate Cancer Trial
ZW191 Hits 64.5% Response Rate at 6.4 mg/kg With Half the Severe Toxicity
Largest Open-Market Insider Buys
Form 4 open-market purchases ranked by dollar amount.
No open-market insider buys reported on this date.
Largest Open-Market Insider Sells
Form 4 open-market sales ranked by dollar amount.
No open-market insider sells reported on this date.
Notable 8-Ks and News
Material events and breaking news with importance score 6 or higher.
Imfinzi Combo Cuts Bladder Cancer Death Risk 42% in Phase III VOLGA Trial
Imdelltra-Imfinzi Combo Cuts Lung Cancer Death Risk 58% in Phase 3
Zolucatetide Hits 72% Response Rate in Desmoid Tumors; FDA Aligns on Phase 3
Melanoma Combo Cuts Recurrence Risk ~42% as Analysts Split on Moderna
Robot Consulting Appeals Nasdaq Delisting, Trading Halt Persists
Audi Pledges $4.2B Georgia Plant Producing 200K SUVs a Year
Climb Bio's pMN Drug Shows B-Cell Depletion, Remission at 12 Weeks in Early Phase 2
BeOne's GPC3 Bispecific Hits 36% ORR in Liver Cancer; Registrational Trials Planned by Year-End
Tesla Slashes Capex to $20B as Operating Income Falls 56%
J&J Sets Mid-2027 DePuy Spin as $20–22B Orthopedics Valuation Circulates; UK Clears Icotyde
Form 144 Notices
Notices that restricted shares may be sold soon — often a precursor to insider selling.
No Form 144 notices filed on this date.
Day boundary: 00:00 ET (America/New_York). Filings accepted late may appear in the next day's recap.